Agoracom Blog Home

Posts Tagged ‘MMJ’

« Older Entries
Newer Entries »

The week in #marijuana deals: Emerald online, #ABcann gets clinical and #Wheaton goes to Uruguay $N.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca $TBP.ca

Posted by AGORACOM-JC at 10:31 AM on Monday, February 5th, 2018

  • Namaste Technologies Inc. and B.C.-based LP Emerald Health Therapeutics Inc., announced on Tuesday that they were joining forces to develop a new e-commerce platform for Emerald products.
  • Emerald will use Namaste’s online technology to sell its cannabis alongside Namaste’s catalogue of “cannabis delivery devices.

Aphria Inc.’s announcement on Monday morning that it was buying little-known Nuuvera Inc. for an implied value of $826 million kicked the week off with a bang. By Friday, however, optimism in the sector had hit a wall. The Canadian Marijuana Index shed more than 30 per cent between Monday and Friday, and the week ended with a volatile day of sell-offs and opportunistic buys. While the cannabis stock market shuddered, companies continued to make deals. Here are a few you may have missed.

Emerald Goes Online

Namaste Technologies Inc., an online retailer of cannabis related products, and B.C.-based LP Emerald Health Therapeutics Inc., announced on Tuesday that they were joining forces to develop a new e-commerce platform for Emerald products. Emerald will use Namaste’s online technology to sell its cannabis alongside Namaste’s catalogue of “cannabis delivery devices.” Emerald will also provide product to Namaste’s subsidiary Cannmart Inc., which is currently applying for a sales-only licence under the ACMPR. Under the deal, the companies will each get 500,000 warrants for the other’s stocks.

Getting Clinical

On Thursday, licensed producer ABcann Global Corp. completed its acquisition of Harvest Medicine Inc., a medical cannabis clinic in Calgary with 9,700 patients, according to the company. ABcann plans to develop additional Harvest Medicine clinics, starting with one in Edmonton that’s expected to open this spring. It paid $1.5 million in cash and issued 1,056,338 shares to Harvest Medicine owners, with more promised if the company hits “certain performance milestones.”

Other deals

Winnipeg-based LP Delta 9 Cannabis Inc., which produces cannabis inside “grow pods” made of repurposed shipping containers, plans to develop a production facility in Southern Alberta with private company Westleaf Cannabis Inc. On Monday the companies announced they had signed a non-binding letter of intent to repurpose an existing building into an operation intended to produce 4,000 kilograms of dried flower a year. Each company will take a 50 per cent stake in the project, which, according to Delta 9, is expected to be up and running as early as Q3 2018.

Cannabis Wheaton Income Corp. entered into an agreement to buy Uruguay-based Inverell S.A. The federally licensed “cannabis operator,” based in Uruguay’s capital Montevideo, has 16 hectares planted and another 574 hectares available for cultivation, according to a press release from Wheaton Income. Wheaton Income is paying around $5.5 million in cash and shares, and another $9.5 million if Inverell hits certain goals.

iAnthus Capital Holdings Inc., which is based in the U.S. but trades on the Canadian Securities Exchange, acquired New York-based Citiva Medical for US$18 million in cash and shares. Citiva holds one of only 10 medical marijuana licences in New York, and plans to open four dispensaries over the next two years. According to Canaccord Genuity Corp. analyst Matt Bottomley, New York’s medical cannabis market could be worth up to $1 billion annually. There are still concerns, however, about how Canadian regulators will deal with Canadian-listed companies operating in the U.S. where the federal government recently announced its intent to enforce cannabis laws more strictly.

Source: http://business.financialpost.com/investing/the-week-in-marijuana-deals-emerald-online-abcann-gets-clinical-and-wheaton-goes-to-uruguay

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on The week in #marijuana deals: Emerald online, #ABcann gets clinical and #Wheaton goes to Uruguay $N.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca $TBP.ca

Tetra Bio-Pharma $TBP.ca Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:45 AM on Monday, February 5th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application  for the Company’s PPP001 prescription smokable dried cannabis product
  • Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug

OTTAWA, ONTARIO–(Feb. 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.

Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug. This trial is expected to be a landmark study, enrolling a total of 946 subjects, evaluating the therapeutic benefits of a cannabinoid prescription drug in improving quality of life and treating pain in terminal cancer patients.

“This is an especially significant and noteworthy milestone for the lead candidate in our product pipeline,” said Bernard Fortier, Tetra’s CEO, “as it positions Tetra to potentially be the first company with a Health Canada approved, cannabinoid-based drug on the market aimed at treating breakthrough pain in cancer patients. The advanced cancer pain market is a $2.4B market1; this is a significant and important opportunity for the Company as our drug PPP001 has the potential to help reduce the reliance on opioids for the management of severe pain.”

The first and main recruitment center of the trial will be in Montreal at Santé Cannabis, Québec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.

The PPP001 Phase 3 trial will evaluate the effects of Tetra’s smokable cannabinoid-based drug made from natural dried cannabis. Tetra previously entered into a supply agreement with Aphria Inc., to use Aphria’s unique blend of dried medical cannabis in its PPP001 clinical trial. Aphria owns an 8.5% stake in Tetra.

As part of the clinical trial, Tetra will also collect the pharmaco-economics evidence required from insurers in order to support the reimbursement of the first cannabis prescription drug. “Today, most private insurance plans do not cover cannabis treatment, nor is public reimbursement available, making this therapeutic option costly for patients. It is very important for us to bring a new therapeutic option for patients in the form of an approved prescription drug and to take action in order to have it reimbursed for patients” commented Bernard Fortier, CEO.

The trial aims to demonstrate that PPP001 eases suffering and facilitates a more serene experience of living and dying in terminal cancer patients. If conclusive, Tetra will submit a filing for a Drug Identification Number (DIN) to Health Canada in 2019, thus providing a new noninvasive treatment to relieve pain for cancer patient. With this approval, Tetra expects to be on time with its previously announced schedule with the development of PPP001, culminating in a potential launch in Canada by Q1, 2020 and in the US by Q3, 2020.

Dr Guy Chamberland, Tetra’s Chief Scientific Officer (CSO) explained that: “The development of PPP001 for patients with advanced cancer is an important commitment for Tetra, given that cancer patients suffer from severe pain which is often accompanied by depression and insomnia. Medical cannabis has been shown to help patients beyond the immediate benefit of pain relief.”

“With the expertise of Santé Cannabis, we expect to demonstrate the clinical benefits of PPP001 on the quality of life of advanced cancer patients. It’s important to note that our clinical program will also address the potential of PPP001 to reduce the reliance on opioids for management of severe pain. We expect that, once it is approved as a drug under prescription, PPP001 will be included over time ahead of opioids treatment for those patients with terminal cancer pain. The Company will continue to maintain a transparent and direct line of communication with Health Canada and the U.S. FDA to ensure that we address the issues required for drug approval. PPP001 is about patients first, ” added Dr. Guy Chamberland.

Tetra worked with Santé Cannabis physicians to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients and have focused the clinical development on a first indication in patients with advanced cancer. The Phase III clinical trial will be performed by the medical team of Santé Cannabis.

“Throughout my clinical experience assessing and following more than 600 medical cannabis patients, cannabis inhalation remains a critical option to provide rapid relief from a wide variety of symptoms associated with advanced cancer, ” said Dr. Antonio Vigano, Principal Investigator of the trial and Research Director of Santé Cannabis. “We will rigorously assess the safety, efficacy and tolerability of PPP001 to support the population of cancer patients by bringing an important therapeutic tool to the same standard of prescription drugs It is great to be celebrating World Cancer Day 2018 with the first large scale clinical study to prove that medical cannabis can ease the suffering and improve quality of life of many cancer patients, particularly when they most need it.”

About Cancer Pain:

In the USA, 1,5 million patients suffer from cancer pain2. Pain is one of the most frightening of all cancer symptoms for patients and their families3. According to statistics published by the American Cancer Society in 20024, 50% to 70% of people with cancer experience some degree of pain, with a quarter of them actually dying in pain. Without adequate relief of their pain, their quality of life is negatively impacted. Furthermore, the incidence of pain in advanced stages of invasive cancer approaches 80% and it is 90% in patients with bone metastases5.

  1. https://decisionresourcesgroup.com/report/141466-biopharma-cancer-pain-2015
  2. Melnikova I. Pain market 2010 ;, doi:10.1038/nrd3226
  3. Winslow M, Seymour J, Clark D. 2005. Stories of cancer pain: a historical perspective. J Pain Symptom Manage, 29:22-31.
  4. American Cancer Society. 2002. Cancer facts and figures 2002 
  5. Pharo GH, Zhou L. 2005. Pharmacologic Management of Cancer Pain. JAOA, 105:S21-28.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9,5% THC and 2,5% CBD.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

For media information, please contact :
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces Increase in Bought Deal Offering to $35 Million $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:05 PM on Thursday, February 1st, 2018

Nlogo

  • Now agreed to purchase 13,726,000 units of the Company on a “bought deal” basis
  • At a price per Unit of $2.55 for gross proceeds of $35,001,300

VANCOUVER, BRITISH COLUMBIA–(Feb. 1, 2018) – NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Namaste Technologies Inc. (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) (“Namaste” or the “Company“), is pleased to announce that it has entered into an amended letter of engagement with Eight Capital and Canaccord Genuity Corp. as co-lead underwriters and joint bookrunners, and including Beacon Securities Limited (together, the “Underwriters”), under which the Underwriters have now agreed to purchase 13,726,000 units of the Company (the “Units“), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $2.55 (the “Issue Price“) for gross proceeds of $35,001,300 (the “Offering“).

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $5,250,195 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $40,251,495.

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $3.15, for a period of 24 months following the closing of the Offering. If, following the closing of the Offering, the volume weighted average price of the Common Shares on the Canadian Securities Exchange is equal to or greater than $6.00 for any 10 consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

The Company intends to use the net proceeds of the Offering to fund inventory and for working capital and general corporate purposes.

The closing date of the Offering is scheduled to be on or about February 27, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.co.uk

www.everyonedoesit.co.uk

Forward-Looking Information

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Increase in Bought Deal Offering to $35 Million $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces Record-Breaking Quarterly Sales of $4.9M Representing a 133% Year-On-Year Increase $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 6:58 PM on Monday, January 29th, 2018

Nlogo

  • Company’s sales for the three months ending on November 30, 2017, were $4.9M,
  • $2.8M or 136% increase in comparison with the Company’s quarter ended November 30, 2016.

VANCOUVER, British Columbia, Jan. 29, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis and certification of the quarterly filings for the first quarter of fiscal 2017. The statements for the period can be accessed on SEDAR at www.sedar.com. The Company’s sales for the three months ending on November 30, 2017, were $4.9M, representing a $2.8M or 136% increase in comparison with the Company’s quarter ended November 30, 2016.   Gross margin also increased to 32% for the three months ended on November 30, 2017 in comparison to 28% for the Company’s quarter ended November 30, 2016.

During the financial reporting period of September 1, 2017 to November 30, 2017, the Company focused on expanding sales in existing territories as well as in emerging markets such as Mexico and Brazil while reducing sales exposure in the United States.

The Company also sold its US assets and operations as a strategic decision to eliminate risk related to US market exposure.

The Company remains focused on achieving profitability and on launching its medical cannabis marketplace, NamasteMD, through our wholly-owned subsidiary, Cannmart Inc.

Quarterly Financial Highlights

  • The majority of revenues were generated by several key markets. The top five countries generated 84% of revenues for the three months ended November 30, 2017. In the previous year the top five countries generated 79% of revenues. The table below depicts gross revenues by country.

  • The Company’s cost of sales for the three months ended November 30, 2017 were $3.4 million (2016 – $1.5 million), which resulted in a gross profit of $1.6 million (2016 – $0.6 million). The gross profit increased by $1.0 million or 167%, which is primarily due to the growth in revenue outside the United States. The gross profit margin increased year over year from 28% to 32% due to better operating efficiencies.
  • Operating costs were $4.7 million (2016 – $1.5 million), which is an increase of $3.2 million. The increase in operating costs is primarily due to non-cash charges of $2.6 million, which included share-based compensation, shares for services, amortization of intangible assets, and depreciation.
  • Selling expenses for the three months ended November 30, 2017 were $1.1 million (2016 – $0.5 million), which is an increase of $0.6 million. The increase is due in part to an increase in advertising expenses of $0.1 million and consulting expenses of $0.2 million. Advertising expenses relate to online search services as well as other online promotional and social media tools utilized by the Company to generate sales. These costs further represent the Company’s significant investment into search engine optimization and its ongoing customer acquisition strategy. In addition to this, there were non-cash expenses related to shares for services of $0.2 million.
  • Consulting expenses relate to compensation amounts paid to various companies and individuals for marketing, order fulfillment, customer service activities, e-commerce product development, back-office e-commerce support and sales commissions. The increase in consulting fees is primarily related to information technology in order to develop current and new revenue channels that the Company is working towards.
  • Administration expenses for the three months ended November 30, 2017 were $3.3 million (2016 – $0.9 million), which is an increase of $2.4 million. The increase is primarily due to share-based compensation of $2.1 million and shares for services of $0.1 million
  • Other expenses for the three months ended November 30, 2017 were $0.3 million (2016 – approximately nil), which is an increase of $0.3 million. The increase is primarily due to amortization of intangibles of $0.2 million, which relates to the amortization of the customers list from the acquisition of Australian Vaporizers.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “During the first quarter ended November 30, 2017, Namaste embarked on implementing many strategic business initiatives focused on expansion in international markets other than the United States. In addition, posting record-breaking revenues, management remains focused on seeking and securing strong partnerships to further accelerate growth going forward. We expect to see significant upside to Namaste’s revenue and profitability as a direct result of the many acquisitions and partnerships that were initiated both during and following this quarter. Management believes there are many more strategic opportunities that exist in the cannabis market that will serve to strengthen Namaste’s position moving forward. In particular the NamasteMD platform will be key driver of growth.  We are extremely excited at where the industry is headed and believe Namaste is well-positioned in 2018 and beyond.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , , ,
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Record-Breaking Quarterly Sales of $4.9M Representing a 133% Year-On-Year Increase $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Receives Health Canada Approval for Phase 2 #Cannabis Oil Trial in Partnership with Sante Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:15 AM on Monday, January 29th, 2018

Logo tetrabiopharma rgb web

  • Announced the approval by Health Canada of a Phase 2 clinical trial
  • Designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients

OTTAWA, ONTARIO–(Jan. 29, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

“To our knowledge, this is the first Health Canada-approved phase 2, randomized, double-blind, placebo-controlled clinical trial using encapsulated medical cannabis oil in Canada,” said Bernard Fortier, Tetra Bio-Pharma’s CEO. According to an Eight Capital analysis1, the cannabis oil market is expected to reach 1.5B$ in 2024.

“This is a significant milestone in our mission to become a global bio-pharmaceutical leader in cannabinoids-based drug development. We currently have a strong pipeline of five cannabinoid-based products, all launched last year and using different delivery systems, in various stages towards Health Canada and FDA approval.”

The Phase 2 trial will be conducted with Montreal-based Santé Cannabis, Quebec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.

According to Health Canada data2, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1.

Dr. Guy Chamberland, Tetra’s Chief Scientific Officer (CSO), also commented that “there is limited scientific and clinical information on the different doses and ratios of medical cannabis oil in the management of pain. This type of clinical trial is required to generate the urgently needed safety and efficacy data required by physicians and pharmacists for the adequate care of patients”.

“We are excited to launch this trial to build the evidence base for medical cannabis in chronic pain, and to demonstrate the leadership of Santé Cannabis on the world stage” said Dr. Antonio Vigano, Research Director of Santé Cannabis and McGill University Associate Professor of Oncology. “At Santé Cannabis, our team observes the impact that cannabis oil has for our patients. For many, medical cannabis can reduce or even eliminate the need for other pharmacological medications. As clinicians and researchers, we must pursue these critical steps to quantify its benefits and to investigate potential risks.”

These studies are part of the Company’s sales and marketing strategy required to effectively penetrate a physician-pharmacist market. The outcome of these studies will also support Tetra’s overall drug development strategy and it is expected that this will allow Tetra to reduce the overall time-to-market for a number of its cannabinoids-based prescription drugs. The company will also use this data to create novel new products that will allow Tetra to further increase its share in the cannabis oil market.

Last year, Tetra launched a number of drug development programs that are expected to lead to the commercialization of cannabinoid-based prescription drugs, making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians to prescribe, and pharmacists to dispense, these medicines to patients in need.

After receiving approval of a phase 1 clinical trial for its PPP005 cannabis oil program in mid-January of this year, Tetra is now launching a phase 2 trial to assess if cannabis oil treatment will reduce the amount of concurrent pain medications and the need for rescue medications to control chronic cancer and non-cancer pain. This phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil. In addition, the study will evaluate the effects on improving symptom burden and on cognition and mood in those chronic pain patients.

Tetra and Santé Cannabis have been preparing for several months to initiate this clinical program. The team at Santé Cannabis has grown to include qualified and experienced personnel in the conduct of clinical trials in compliance with Good Clinical Practices. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population, as well as provide Tetra with critical knowledge of the benefits of different ratios of THC and CBD in pain management.

1: Cannabis Sector, Eight Capital Estimates, July 2017

2: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html]

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

Tags: , , , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Receives Health Canada Approval for Phase 2 #Cannabis Oil Trial in Partnership with Sante Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces 5% Equity Purchase LOI with Cannbit Ltd. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, January 18th, 2018

Nlogo

  • Company has signed a non-binding Letter of Intent with Israeli medical cannabis producer, Cannbit Ltd
  • Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties

VANCOUVER, British Columbia, Jan. 18, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company has signed a non-binding Letter of Intent (“LOI”) with Israeli medical cannabis producer, Cannbit Ltd (“Cannbit)” whereby the companies propose to enter into a share purchase agreement and/or a subscription agreement (the “Agreement”) whereby Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties. Cannbit will also offer Namaste a first right of refusal to purchase an additional 5% equity in shares at the same valuation.

Further to the Company’s September 15th, 2017 announcement of signing a Wholesale Supply Agreement (“Supply Agreement”) with Cannbit, Namaste intends to purchase high-quality medical grade cannabis from Cannbit through the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”). The Company is pleased to have the opportunity to participate in an equity position with Cannbit and in developing a long-term relationship that will be mutually beneficial to both parties. Cannmart is a late stage applicant for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) medical cannabis “sale-only” license. Through Cannmart, Namaste plans to offer the largest variety of medical cannabis products to its patients through the sourcing of both domestic and internationally imported products. Namaste hopes to leverage its vast expertise with e-commerce, conversion rate optimization and enterprise technology to create Canada’s leading online marketplace for medical cannabis.

Terms of the LOI:

  • Namaste will make an investment in Cannbit in exchange for 5% equity, whereby the amount will be determined by a valuation agreed to by both parties.
  • Namaste will have a first right of refusal to purchase an additional 5% equity position in Cannbit, at the same valuation as originally agreed upon, for a period of one year from the date of execution of the proposed agreement.
  • Closing of the proposed agreement will be contingent upon negotiating and execution of definitive documentation and approval of the terms of the agreement by each party’s respective board of directors and shareholders, if applicable, and by the Canadian Securities Exchange, if applicable.

Namaste’s strategic investment in Cannbit, as well as other domestic and international licensed producers of medical cannabis, will bring value to the company in securing strong partnerships with leading cannabis cultivators to ensure ample supply of the largest variety of high-quality medical cannabis in the Canadian market. Namaste plans to seek additional opportunities by implementing Cannmart’s business model in other regions where the Company maintains significant market share.

Sean Dollinger, President and CEO of Namaste comments: “We’re very much looking forward to working with Cannbit and their team to import exceptionally high-quality medical cannabis into the Canadian market. Namaste expects to see strong value in this investment, as well as through the supply arrangement with Cannbit. We will continue to seek relationships with leading cultivators domestically and abroad. We are highly focused on creating a superior user experience and better availability of products for our patients, and believe this transaction will help us achieve that goal. Thank you to Cannbit’s management team for working hard to secure this LOI and Supply Agreement. We look forward to many years of business together and are excited at the opportunity to give Canadians access to the Israeli cannabis market.”

Yaron Razon, President and CEO of Cannbit Comments “We are very excited to have this partnership and strategic cooperation with Namaste. We believe Namaste is well-positioned with an impressive global marketing and distribution platform and led by a brilliant management team. Together with Namaste, Cannbit will reach many patients across the world with premium medical grade cannabis to help treat their health conditions. We anticipate exploring new opportunities with Namaste and are looking forward to working together soon.”

About Cannbit Ltd.

Cannbit is focused on growing high-quality medical-grade cannabis with advanced technology and agriculture platform while utilizing the best human resources to produce the highest level of quality available that will effectively treat a wide range of illnesses. The Israeli government is expected to approve the export of medical cannabis and Cannbit intends to become Israel’s leading exporter for medical cannabis to legal jurisdictions around the globe. Cannbit’s facility is 4,000 square meters with an additional 10,000 square meters available for expansion and is located in Neot Hakikar, an area well known in the Israeli agricultural community with clear advantages in the cold seasons. Our cultivation is carried out in a sophisticated greenhouse that provides ideal conditions for a variety of cannabis strains. Cannbit’s management is comprised of a group of industry professionals in relevant disciplines.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces 5% Equity Purchase LOI with Cannbit Ltd. $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, January 17th, 2018

Nlogo

  • Reaffirms its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions
  • Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments

VANCOUVER, British Columbia, Jan. 17, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) would like to reaffirm its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions. Further to the Company’s Nov 28, 2017 press release, and in lieu of the recent rescission of the Cole Memorandum by US Attorney General Jeff Sessions, Namaste’s position on staying out of the US cannabis market remains firm. The Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments. Namaste is highly focused on the expansion of its Canadian operations through the launch of its online medical cannabis marketplace. Management will have no involvement in operations or investments in any illegal jurisdictions which present any risk to the Company and/or its shareholders.

On January 12, 2018, the Canadian Securities Administrators (“CSA”) issued a statement following the rescission, whereby the CSA gave notice that it would re-examine its disclosure-based policy in relation to Canadian cannabis companies with any US operations or investments. Namaste believes that the CSA’s statement is in-line with the Company’s position and short-term outlook on the cannabis market in the United States.

Namaste will continue to focus on expansion of its international operations in progressive, legal markets by leveraging its technology and existing databases of cannabis consumers in countries around the world. Namaste, through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is developing an online marketplace for medical cannabis that will offer patients the largest variety of product sourced from domestic and international producers. The launch of Cannmart is significant to Namaste, as the Company intends to follow the same strategy in other legal markets where it has established a strong presence.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to have divested our US assets and operations. Namaste will continue focusing its efforts on progressive, legal markets like Canada and emerging legal cannabis markets like Australia and will remain uninvolved with any US cannabis operations until there are major changes to US federal laws.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tags: , , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Namaste $N.ca $NXTTF Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net Production $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:17 AM on Tuesday, January 16th, 2018

Nlogo

  • Participating as a lead order in a private placement offering by Atlas Growers Ltd.
  • In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. have entered in to a Supply Agreement
  • Atlas agreed to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas

VANCOUVER, British Columbia, Jan. 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company is participating as a lead order in a private placement offering (“Private Placement”) by Atlas Growers Ltd. (“Atlas”), which is a late-stage applicant for an Access to Cannabis for Medical Purposes (“ACMPR”) cultivation and sales license. In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) have entered in to a Supply Agreement (the “Supply Agreement”) whereby Atlas agrees to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas.

The Company’s participation in the Private Placement and subsequent Supply Agreement offer significant value to Namaste shareholders not only as an investment, but also in securing a reliable supply of high quality medical cannabis. The Company believes Atlas’ strong management team and business plan provide a strategic partnership opportunity with Atlas to ensure a guaranteed cannabis supply to Namaste, while at the same time broadening Atlas’ exposure to the market via Cannmart’s online retail channels. Namaste has completed the Subscription Agreement under the terms of the Private Placement, for C $200,000 in exchange for 200,000 Class B Common shares of Atlas stock at a price of C $1.00 per common share. The Supply Agreement will allow Cannmart to purchase bulk quantities of medical cannabis from Atlas based on the terms below.

Supply Agreement Terms

  • Atlas commits to Cannmart a first right of refusal to purchase up to 20% of Atlas’ production
  • The term of the Supply Agreement is 24 months
  • Purchase orders are to be submitted at least 14 days in advance of requested delivery date
  • Payment terms are 30 days from delivery of a purchase order
  • Cannmart will be responsible for delivery charges
  • The Supply Agreement is subject to both companies receiving their ACMPR licenses.

Namaste will continue to explore additional opportunities for investments in domestic and international medical cannabis producers as it sees great value in securing equity and building a strong and reliable supply chain for Cannmart’s patients. Namaste plans to leverage its vast e-commerce expertise and technology, along with its existing consumer databases and site traffic, to create the largest online marketplace for medical cannabis in Canada. This strategic investment in Atlas clearly defines the Company’s strategy in developing strong supply relationships to achieve its goals. The Canadian market offers some unique opportunities as it relates to craft and/or boutique producers, and Namaste believes this niche will add significant value to its platform.   Canada has a long history of producing some of the highest quality and most sought-after cannabis in the world, and it is Namaste’s intention to ensure all producers have access to its distribution channels. Namaste expects to see a growing demand for the cannabis produced in these markets, much like that seen in the craft beer and wine industry. This partnership demonstrates the Company’s intention to leverage a broad range of supply chains, in an attempt to meet the wants and needs of our patients.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to be participating in this opportunity with Atlas and their team. We believe that Atlas will be an amazing strategic partner for Namaste in its ability to guarantee a reliable supply of cannabis for Cannmart. We are looking forward to working with Atlas to provide value and exposure for their brand. Namaste will continue to seek opportunities for partnerships with large and small ACMPR producers and will also focus on growing our vendor database to include premium craft cannabis brands. The opportunity to participate in this private placement brings value to the company as an investment but also in implementation of our strategy to become the most diversified marketplace for medical cannabis.”

Sheldon Croome, President and CEO of Atlas comments: “Our team is pleased to work with Namaste by providing our array of high quality cannabis products to their customers. In partnering with Namaste, both companies gain a significant strategic advantage as the market moves towards recreational legalization in 2018, and as the medical cannabis market expands. Namaste will be instrumental in bringing Atlas’ products to Eastern Canadian customers with the fastest possible delivery times, which we feel to be of excellent value to the end consumer. We are excited to bring additional value to Namaste and look forward to a strong, long term partnership.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Further information on Atlas can be accessed through the link below:

www.atlasgrowers.com

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net Production $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:38 AM on Wednesday, January 10th, 2018

15233 mcoa

  • Provides a final report on the first phase of their industrial hemp project in New Brunswick
  • In this first phase of MCOA’s and GHG’s multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season
  • Objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region

Escondido, California–(January 10, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group, Inc. (“GHG”) (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF) are pleased to provide a final report on the first phase of their industrial hemp project in New Brunswick.

On September 5, 2017, MCOA and GHG announced their joint venture to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada.

In this first phase of MCOA’s and GHG’s (the “Partners”) multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season (see Phase One Hemp Trial Results below). For this phase of the project, the Partners only grew hemp for research purposes, as this was the first time in 20 years that industrial hemp was grown in the region. The objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region.

The Partners are preparing for proposed changes to Canadian legislation expected in 2018, that will permit cannabidiol (CBD) extraction from industrial hemp. Health Canada is currently consulting industry representatives regarding regulations that will accompany the new cannabis legislation expected by July 1, 2018.

The Partners are now focusing on the next season of crops. Farmers have been recruited and a minimum of 125 acres of hemp cultivation is planned for 2018, with the goal of increasing the acreage under cultivation to 1,000 acres by year three of the project. This first commercial crop will focus on CBD extraction. The Partners are currently considering sites in northeast New Brunswick to locate their processing facilities. In addition, discussions are underway regarding the purchase of extraction equipment for cannabinoids, and straw processing equipment for building materials. The companies expect the facilities to be in place and operational for the 2018 harvest in October.

Under the joint venture MCOA will facilitate access to international markets for the project’s CBD production, product development and distribution, while GHG will provide technical and management expertise. MCOA has Right of First Refusal as the primary off-taker of the cannabinoids from all future hemp cultivation projects.

RENEWAL OF GHG’S HEMP LICENSE IN CANADA

GHG’s industrial hemp license was renewed for 2018. Under current legislation, hemp flowers and leaves grown under field conditions cannot be processed. It is expected that this will be allowed under new 2018 regulations, but will still require additional licenses: one to extract the CBD and another to sell CBD for medical or non-medical purposes. In anticipation of this change, GHG will be applying for a license under the Narcotics Control Regulations (NCR) to extract CBD, and an additional license under the Access to Cannabis for Medical Purposes (ACMPR) to sell it to wholesale and retail customers in Canada.

FINAL TRIAL RESULTS

The trial consisted of fifteen test plots with three different varieties and as many planting densities of hemp, in two different locations east and west of Bathurst.

The trials were sampled, and collected materials were measured at Collège Communautaire du Nouveau Brunswick (CCNB), Grand Falls laboratory, where standard drying and measuring procedures were applied to the hemp straw, flowers, and leaves. Straw yields averaged 1.0-2.5 T/ha, whereas the combined flowers and leaves of the plant averaged 1.25-2.10 T/ha. The Partners are confident that with an earlier planting date, adequate soil preparation, and a higher fertilizer application, yields will be improved in future seasons.

Cannabinoid analysis of the flowers and leaves was completed by RPC – Science & Engineering (RPC), an accredited laboratory located in Fredericton, NB. Contrary to expectations leaves, rather than the flowers, contained a greater concentration of CBD, largely explained by laboratory procedures. The highest concentration that was found was the CFX-1 leaf sample that resulted in 1.46% for the 30 kg/ha plant density compared to 1.17% for the flowers. Also, it should be noted that the CBD concentration in flowers is consistently higher at densities of 30 kg/ha across all varieties that were tested.

Frank Giese, an advisor to GHG, will consult on the 2018 cultivation to assist in increasing both plant yield and cannabinoid production. Through his experience, he has bridged the fundamentals of scientific research and hemp/cannabis breeding, as well as the use and development of modern cultivation and processing techniques in his breeding work. He has become proficient in breeding cannabinoid rich varieties of hemp, as well as being very experienced in auto flower breeding.

Donald Steinberg, CEO of MCOA, stated, “We are excited to complete the first phase of industrial hemp trials in Canada, and we look forward to continue expanding operations in Canada. Our joint venture with GHG allows MCOA the opportunity to expand the Company’s operations on an international level. Both Companies are excited about the endless possibilities for hemp derived CBD product this year in Canada.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and value, and establish a greater collective valuation.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 11:10 AM on Friday, January 5th, 2018

  • Medical research forcing an end to prohibition
  • “I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.
  • In recent months, more than a dozen countries have legalized medical marijuana

Medical marijuana consumers in Prague rang in 2018 with a new Canadian import, Tilray Milled Cannabis, a high THC marijuana product grown on Vancouver Island.

The Czech Republic is just the latest nation to sell Canadian weed, joining Germany, Australia, New Zealand and a growing list of other nations which are turning to Canada as a safe and legal source for medical grade cannabis.

In recent months, more than a dozen countries have legalized medical marijuana. New laws are pending in at least a dozen more as national regulators and even the World Health Organization recognize legitimate medical uses for a drug which had long been banned under international treaties.

The moves have sparked an unprecedented demand for legally grown, high quality marijuana, as well as the oil which is extracted from it. Seven Canadian producers have been granted licences to export the crop. By the end of March they will have sent 528 kilograms of dried cannabis flower and 911 litres of oil overseas. That may well be just an initial trickle, as the floodgates open on an international medical cannabis market.

“I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.

Brendan Kennedy of Tilray says Canada is the source of the safest product when regulators in other countries go looking for medical marijuana. (Evan Mitsui/CBC)

“I think it means that we’ll be a global player,” he says, stressing this is a positive development for the Canadian economy. “This could be our opportunity to be viewed the same as we are in mining or hockey. We’ll be world class and be world leaders and I think that will stay to be the case for a very, very long time.”

Medical research forcing an end to prohibition

For decades an international ban on the production and use of cannabis kept to a minimum any legitimate research into potential medical uses. Prohibition ensured that marijuana cultivation stayed in the hands of illegal growers, and distribution was limited to the criminal underground.

But many users saw value in cannabis as treatment for a variety of conditions, ranging from controlling epileptic seizures to pain relief to stress control.

Israeli scientist Raphael Mechoulam began limited research on the drug in the early 1960s, which led to the discovery of the human endocannabinoid system. By the mid-1990s, scientists determined that cannabinoid receptors play a vital role in the function of the human body. For the first time synthetic cannabinoid derivatives were approved for medical use, primarily for the treatment of nausea and wasting syndrome.

At the same time anecdotal evidence was building to suggest cannabis could have other, more widespread medical uses. Patients who claimed benefits from cannabis went to court seeking the right to use marijuana as medicine without facing the risk of criminal prosecution.

In 2000 the Ontario Court of Appeal ruled that Terry Parker, a man with severe epilepsy, should have the right to use marijuana to moderate his severe seizures.

One year later, Canada’s Medical Marijuana Access Program was introduced, allowing patients who had obtained a doctor’s consent to grow their own marijuana under a special permit. By 2013 more than 28,000 Canadians had been granted personal use production licences, leading to a flood of unregulated home-grow operations, and along with it a risk of fires, mould contamination in homes, and legally grown weed being diverted to the black market.

In an effort to crack down on the home grow-ops, the Harper Conservative government introduced new legislation that established legal grow operations which could provide medical marijuana through a mail order service. The Marijuana for Medical Purposes regulations, enacted in 2014, set Canada apart as the first nation to establish a regulated commercial cannabis cultivation industry.

Canadian pot finds a role in the world market

As Canada moves towards legal recreational weed in July, the number of licensed growers has swelled to 84, production is skyrocketing, and research into new growing techniques and improved strains is increasing exponentially. This has placed Canada in a unique role as other nations scramble to find safe and legal supplies of medical cannabis.

Cam Battley, executive vice president of Aurora, shows off Aurora Vie’s Pointe-Claire, Que., facility. Canadian producers have expertise in greenhouse technology, extraction methods, strains and genetics. (CBC)

“When regulators in other countries are looking for a product, Canada is really the source of the safest product. It’s the safest bet,” explains Brendan Kennedy, the CEO of Nanaimo-based Tilray, a pioneer in cannabis exports.

Tilray is among several Canadian producers already exporting to Germany, which established a widespread marijuana access program last spring. Not only is cannabis stocked in German pharmacies, the government pays for the drug under its government health insurance program.

Until it can establish a domestic industry, Germany is importing from Canada. Along with Tilray, Canadian producers Aurora, Cronos and Canopy Growth are tapping the German market. Aurora has even gone a step further, purchasing pharmaceutical supplier Pedanios, with an eye to expanding its distribution in the European market.

Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. Several others are following. A report published in November places the value of the European cannabis market at $84 billion Cdn a year.

That’s led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.

Beyond exports, Canada has expertise

“Part of the reason we decided to invest in a cultivation facility in Portugal was that we also saw a massive increase in demand for medical cannabis product in the EU,” explains Kennedy, who sees a bright future well beyond Canadian exports.

Canadian expertise in growing and greenhouse technology, extraction methods, strains and genetics, along with plain old business know-how, are also in demand. In addition to exports, Canada’s cannabis companies are also teaming up with local partners to build facilities in Germany, Denmark and Israel.

Australia is seen as another prize for Canadian producers. When it announced last February that it would allow importation, Canadian producers Aurora, CannTrust, Canopy, MedReleaf and Tilray swooped in, not only with bags of weed and vials of oil, but with partnerships to build facilities there.

Peru and Mexico have also passed legislation to legalize medical cannabis, and Canadian companies are promising further announcements soon. Overall, they say, the world market could be worth around $200 billion.

What it all means

The rapid legalization of medical cannabis has spurred new research into potential treatments using the drug. In Israel, where the medical research began, there are about 120 trials underway using components of the marijuana plant.

Neil Closner, CEO of Ontario-based MedReleaf, believes Canadian medical marijuana producers have the potential to become global giants. (Canadian Press)

As cures and treatments are discovered and proven, the role of cannabis is sure to expand, creating even greater potential beyond flowers and oil. CEO of Markham-based MedReleaf Neil Closner believes at least two or three of Canada’s producers will become global giants.

“I think overall who wins is Canada. I think we’ve got a leg up on the rest of the world, which is very exciting at a national level for us. I’d like to think that MedReleaf is strongly positioned to be one of the few handfuls of global winners.”

And while California is the latest U.S. state to legalize marijuana, American producers are shut out of the global market because of the federal prohibition on the drug.

That leaves Canada room to pursue the international market and all the potential riches that go with it.

Source: http://www.cbc.ca/news/business/medical-marijuana-canadian-export-1.4470407

Tags: , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »